Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs.

Mihalopoulos C, Magnus A, Lal A, Dell L, Forbes D, Phelps A.

Aust N Z J Psychiatry. 2015 Apr;49(4):360-76. doi: 10.1177/0004867414553948. Epub 2014 Oct 27.

PMID:
25348698
2.

Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.

Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R, Fernandes LN.

Hepatol Res. 2014 Sep;44(9):956-63. doi: 10.1111/hepr.12235. Epub 2013 Nov 11.

PMID:
24033861
3.

Stores Healthy Options Project in Remote Indigenous Communities (SHOP@RIC): a protocol of a randomised trial promoting healthy food and beverage purchases through price discounts and in-store nutrition education.

Brimblecombe J, Ferguson M, Liberato SC, Ball K, Moodie ML, Magnus A, Miles E, Leach AJ, Chatfield MD, Ni Mhurchu C, O'Dea K, Bailie RS.

BMC Public Health. 2013 Aug 12;13:744. doi: 10.1186/1471-2458-13-744.

4.

Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis.

Kremer S, Lamy J, Magnus A, Oesterle H, Jeantroux J, Trunet S, Armspach JP, Dietemann JL, de S├Ęze J.

Neurology. 2013 Jul 16;81(3):206-10. doi: 10.1212/WNL.0b013e31829bfdb9. Epub 2013 Jun 12.

PMID:
23761623
5.

Which interventions offer best value for money in primary prevention of cardiovascular disease?

Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T.

PLoS One. 2012;7(7):e41842. doi: 10.1371/journal.pone.0041842. Epub 2012 Jul 23.

6.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T.

BMC Public Health. 2012 Jun 1;12:398. doi: 10.1186/1471-2458-12-398.

7.

The economic gains of achieving reduced alcohol consumption targets for Australia.

Magnus A, Cadilhac D, Sheppard L, Cumming T, Pearce D, Carter R.

Am J Public Health. 2012 Jul;102(7):1313-9. doi: 10.2105/AJPH.2011.300453. Epub 2012 May 17.

8.

The economic benefits of reducing physical inactivity: an Australian example.

Cadilhac DA, Cumming TB, Sheppard L, Pearce DC, Carter R, Magnus A.

Int J Behav Nutr Phys Act. 2011 Sep 24;8:99. doi: 10.1186/1479-5868-8-99.

9.

The societal benefits of reducing six behavioural risk factors: an economic modelling study from Australia.

Cadilhac DA, Magnus A, Sheppard L, Cumming TB, Pearce DC, Carter R.

BMC Public Health. 2011 Jun 21;11:483. doi: 10.1186/1471-2458-11-483.

10.

Economic benefits of achieving realistic smoking cessation targets in Australia.

Magnus A, Cadilhac D, Sheppard L, Cumming T, Pearce D, Carter R.

Am J Public Health. 2011 Feb;101(2):321-7. doi: 10.2105/AJPH.2009.191056. Epub 2010 Dec 16.

11.

Assessing cost-effectiveness in obesity (ACE-obesity): an overview of the ACE approach, economic methods and cost results.

Carter R, Moodie M, Markwick A, Magnus A, Vos T, Swinburn B, Haby MM.

BMC Public Health. 2009 Nov 18;9:419. doi: 10.1186/1471-2458-9-419.

12.

The cost-effectiveness of removing television advertising of high-fat and/or high-sugar food and beverages to Australian children.

Magnus A, Haby MM, Carter R, Swinburn B.

Int J Obes (Lond). 2009 Oct;33(10):1094-102. doi: 10.1038/ijo.2009.156. Epub 2009 Aug 4.

PMID:
19652656
13.

Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative.

Carter R, Vos T, Moodie M, Haby M, Magnus A, Mihalopoulos C.

Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):593-617. doi: 10.1586/14737167.8.6.593.

PMID:
20528370
14.

Measuring the impact of intimate partner violence on the health of women in Victoria, Australia.

Vos T, Astbury J, Piers LS, Magnus A, Heenan M, Stanley L, Walker L, Webster K.

Bull World Health Organ. 2006 Sep;84(9):739-44.

15.

A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project.

Haby MM, Vos T, Carter R, Moodie M, Markwick A, Magnus A, Tay-Teo KS, Swinburn B.

Int J Obes (Lond). 2006 Oct;30(10):1463-75.

PMID:
17003807
16.

Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.

Swahn BM, Xue Y, Arzel E, Kallin E, Magnus A, Plobeck N, Viklund J.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1397-401. Epub 2005 Dec 5.

PMID:
16337120
17.

Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services.

Vos T, Haby MM, Magnus A, Mihalopoulos C, Andrews G, Carter R.

Aust N Z J Psychiatry. 2005 Aug;39(8):701-12.

PMID:
16050924
18.

Assessing cost-effectiveness of drug interventions for schizophrenia.

Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):44-54.

PMID:
15660705
19.

Assessing Cost-Effectiveness--Mental Health: introduction to the study and methods.

Haby MM, Carter R, Mihalopoulos C, Magnus A, Sanderson K, Andrews G, Vos T.

Aust N Z J Psychiatry. 2004 Aug;38(8):569-78.

PMID:
15298579
20.

Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions.

Mihalopoulos C, Magnus A, Carter R, Vos T.

Aust N Z J Psychiatry. 2004 Jul;38(7):511-9.

PMID:
15255823
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk